Pfizer and BIND Therapeutics, Inc. have extended the terms of their global collaboration through March 2016 to create Accurins that optimize two of Pfizer’s targeted oncology drugs. The collaboration was established in April 2013 under which Bind employs its nanomedicine platform to develop targeted and programmable therapeutics known as Accurins.   Pfizer has the exclusive option to pursue development and commercialization of the Accurins selected, at which point Pfizer will have responsibility...